ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 206 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2020. The put-call ratio across all filers is 0.50 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $8,000 | -27.3% | 127 | -18.6% | 0.00% | 0.0% |
| Q1 2022 | $11,000 | -21.4% | 156 | -6.0% | 0.00% | 0.0% |
| Q4 2021 | $14,000 | -6.7% | 166 | +1.2% | 0.00% | -33.3% |
| Q3 2021 | $15,000 | +15.4% | 164 | +20.6% | 0.00% | +50.0% |
| Q2 2021 | $13,000 | -13.3% | 136 | 0.0% | 0.00% | -33.3% |
| Q1 2021 | $15,000 | -21.1% | 136 | 0.0% | 0.00% | -40.0% |
| Q4 2020 | $19,000 | +72.7% | 136 | 0.0% | 0.01% | +25.0% |
| Q3 2020 | $11,000 | 0.0% | 136 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $11,000 | +83.3% | 136 | -2.9% | 0.00% | +33.3% |
| Q1 2020 | $6,000 | – | 140 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
| Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
| Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
| SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
| Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
| FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
| CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
| Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
| Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |